Indeed, decreased expression of Nrf2, which protects cells against oxidative stress [263] and reduced activity of HO-1, an enzyme contributing to Nrf2 pathway activation [264], was described in CIS-treated cardiomyocytes. Here, HMOX1 is linked to in situ carcinoma.